Details

Autor(en) / Beteiligte

• Bonam, Srinivasa Reddy
• Kaveri, Srini V.
• Sakuntabhai, Anavaj
• Gilardin, Laurent
• Bayry, Jagadeesh

Titel

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients

Ist Teil von

• Cell reports. Medicine, 2020-05, Vol.1 (2), p.100016-100016, Article 100016

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as of May 8, 2020. Currently, there are no specific COVID-19 therapies. Most patients depend on mechanical ventilation. Current COVID-19 data clearly highlight that cytokine storm and activated immune cell migration to the lungs characterize the early immune response to COVID-19 that causes severe lung damage and development of acute respiratory distress syndrome. In view of uncertainty associated with immunosuppressive treatments, such as corticosteroids and their possible secondary effects, including risks of secondary infections, we suggest immunotherapies as an adjunct therapy in severe COVID-19 cases. Such immunotherapies based on inflammatory cytokine neutralization, immunomodulation, and passive viral neutralization not only reduce inflammation, inflammation-associated lung damage, or viral load but could also prevent intensive care unit hospitalization and dependency on mechanical ventilation, both of which are limited resources. [Display omitted] An overreactive immune response, cytokine storm, and development of acute respiratory distress syndrome characterize severe cases of COVID-19. Bonam et al. present a Perspective on diverse immunotherapeutic approaches based on the neutralization of inflammatory cytokines, immunomodulation, and passive viral neutralization for treating severely ill COVID-19 patients.